CN100352807C - 被取代的哌啶化合物 - Google Patents

被取代的哌啶化合物 Download PDF

Info

Publication number
CN100352807C
CN100352807C CNB038041308A CN03804130A CN100352807C CN 100352807 C CN100352807 C CN 100352807C CN B038041308 A CNB038041308 A CN B038041308A CN 03804130 A CN03804130 A CN 03804130A CN 100352807 C CN100352807 C CN 100352807C
Authority
CN
China
Prior art keywords
alkyl
piperidines
hydroxypropyl
dichlorophenoxy
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038041308A
Other languages
English (en)
Chinese (zh)
Other versions
CN1633414A (zh
Inventor
莉莲·阿尔卡雷兹
马克·弗伯
马克·珀迪
布赖恩·斯普林索普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200465A external-priority patent/SE0200465D0/xx
Priority claimed from SE0202673A external-priority patent/SE0202673D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1633414A publication Critical patent/CN1633414A/zh
Application granted granted Critical
Publication of CN100352807C publication Critical patent/CN100352807C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
CNB038041308A 2002-02-18 2003-02-17 被取代的哌啶化合物 Expired - Fee Related CN100352807C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0200465A SE0200465D0 (sv) 2002-02-18 2002-02-18 Chemical compounds
SE02004653 2002-02-18
SE02026730 2002-09-09
SE0202673A SE0202673D0 (sv) 2002-09-09 2002-09-09 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB200610110091XA Division CN100564358C (zh) 2002-02-18 2003-02-17 一种制备4-(3,4-二氯苯氧基)哌啶的方法

Publications (2)

Publication Number Publication Date
CN1633414A CN1633414A (zh) 2005-06-29
CN100352807C true CN100352807C (zh) 2007-12-05

Family

ID=27736686

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038041308A Expired - Fee Related CN100352807C (zh) 2002-02-18 2003-02-17 被取代的哌啶化合物

Country Status (22)

Country Link
US (1) US7709500B2 (enExample)
EP (1) EP1478624B1 (enExample)
JP (1) JP4435571B2 (enExample)
KR (1) KR20040084920A (enExample)
CN (1) CN100352807C (enExample)
AR (1) AR038566A1 (enExample)
AT (1) ATE480518T1 (enExample)
AU (1) AU2003206554B2 (enExample)
BR (1) BR0307477A (enExample)
CA (1) CA2472822A1 (enExample)
CO (1) CO5611135A2 (enExample)
DE (1) DE60334074D1 (enExample)
IL (1) IL195011A0 (enExample)
IS (1) IS7381A (enExample)
MX (1) MXPA04007906A (enExample)
NO (1) NO20043899L (enExample)
NZ (1) NZ534296A (enExample)
PL (1) PL372538A1 (enExample)
RU (2) RU2330019C2 (enExample)
SG (1) SG149695A1 (enExample)
TW (1) TW200303304A (enExample)
WO (1) WO2003068743A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US7521560B2 (en) 2004-06-29 2009-04-21 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
SE0403003D0 (sv) * 2004-12-09 2004-12-09 Astrazeneca Ab Chemical compound 1
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
WO2007014054A2 (en) * 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200734305A (en) * 2005-08-02 2007-09-16 Astrazeneca Ab New salt III
TW200738635A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
WO2007109160A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
TW200812582A (en) * 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
CA2694284A1 (en) * 2007-06-29 2009-01-08 Jennifer Cossrow Heterocyclic compounds useful as raf kinase inhibitors
JP5588167B2 (ja) * 2009-12-28 2014-09-10 ライオン株式会社 育毛養毛剤、毛周期変換剤および育毛養毛組成物
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
RU2606121C2 (ru) * 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
SG10201608577RA (en) * 2012-04-13 2016-12-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
US20160090383A1 (en) 2013-05-08 2016-03-31 Actelion Pharmaceuticals Ltd. Antibacterial phthalide derivatives
MA41140A (fr) * 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN107674013B (zh) * 2016-08-02 2022-05-24 上海迪诺医药科技有限公司 多环化合物、其制备方法、药物组合物及应用
EP4406609A3 (en) 2017-05-30 2024-10-02 Day One Biopharmaceuticals, Inc. Method for producing optically active compound
WO2023183850A1 (en) 2022-03-23 2023-09-28 Ideaya Biosciences, Inc. Piperazine substituted indazole compounds as inhibitors of parg
KR102650222B1 (ko) 2023-02-14 2024-03-21 (주)오송 살균제용 조성물 및 이를 이용한 제품

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
WO2000012478A1 (en) * 1998-08-31 2000-03-09 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
WO2000029377A1 (en) * 1998-11-17 2000-05-25 F. Hoffmann-La Roche Ag 4-aroyl-piperidin-ccr-3 receptor antagonists iii
WO2000035499A1 (en) * 1998-12-15 2000-06-22 Bausch & Lomb Incorporated Contact lens cleaner comprising biguanide, tyloxapol, and poloxamine
WO2000035453A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000058305A1 (en) * 1999-03-26 2000-10-05 Astrazeneca Ab Novel compounds
WO2001002381A1 (en) * 1999-07-02 2001-01-11 Astrazeneca Uk Limited Piperazine derivatives as modulators of chemokine receptor activity
WO2001062729A1 (en) * 2000-02-25 2001-08-30 Astrazeneca Ab Novel compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
IL118768A (en) * 1995-07-12 2000-10-31 Akzo Nobel Nv Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation
JPH0977742A (ja) 1995-09-12 1997-03-25 Kyorin Pharmaceut Co Ltd 新規なベンズアミド誘導体
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
IL129430A0 (en) 1996-10-28 2000-02-17 Schering Corp Substituted arylalkylamines as neurokinin antagonists
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
EP1131290B1 (en) 1998-11-20 2008-02-20 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
EP1133465B1 (en) 1998-11-25 2004-07-14 Gene Therapy Systems, Inc. Amphiphilic polyamine compounds
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU770042B2 (en) * 1998-12-18 2004-02-12 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035449A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2350730A1 (en) 1998-12-18 2000-06-22 George V. Delucca N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6489354B1 (en) * 1999-03-02 2002-12-03 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6358979B1 (en) * 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
SE9902765D0 (sv) * 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
WO2001098269A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1294690A2 (en) 2000-06-21 2003-03-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2413245A1 (en) * 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
US6855553B1 (en) 2000-10-02 2005-02-15 3M Innovative Properties Company Sample processing apparatus, methods and systems
WO2002030899A1 (en) 2000-10-09 2002-04-18 Novartis Ag N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists
US6642256B2 (en) 2000-12-21 2003-11-04 Warner-Lambert Company Llc Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
SE0100087L (sv) * 2001-01-12 2002-06-18 Volvo Lastvagnar Ab Tätningslist samt komponent innefattande en första och en andra del samt en tätningslist
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
GB0117899D0 (en) * 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
TW200812582A (en) * 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
WO2000012478A1 (en) * 1998-08-31 2000-03-09 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
WO2000029377A1 (en) * 1998-11-17 2000-05-25 F. Hoffmann-La Roche Ag 4-aroyl-piperidin-ccr-3 receptor antagonists iii
WO2000035499A1 (en) * 1998-12-15 2000-06-22 Bausch & Lomb Incorporated Contact lens cleaner comprising biguanide, tyloxapol, and poloxamine
WO2000035453A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000058305A1 (en) * 1999-03-26 2000-10-05 Astrazeneca Ab Novel compounds
WO2001002381A1 (en) * 1999-07-02 2001-01-11 Astrazeneca Uk Limited Piperazine derivatives as modulators of chemokine receptor activity
WO2001062729A1 (en) * 2000-02-25 2001-08-30 Astrazeneca Ab Novel compounds
WO2001062728A1 (en) * 2000-02-25 2001-08-30 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP1478624B1 (en) 2010-09-08
CO5611135A2 (es) 2006-02-28
IL195011A0 (en) 2009-08-03
AU2003206554A1 (en) 2003-09-04
NO20043899L (no) 2004-11-17
KR20040084920A (ko) 2004-10-06
AR038566A1 (es) 2005-01-19
AU2003206554B2 (en) 2009-05-07
US7709500B2 (en) 2010-05-04
NZ534296A (en) 2006-01-27
TW200303304A (en) 2003-09-01
MXPA04007906A (es) 2004-10-15
DE60334074D1 (de) 2010-10-21
US20050107428A1 (en) 2005-05-19
RU2330019C2 (ru) 2008-07-27
BR0307477A (pt) 2004-11-09
CN1633414A (zh) 2005-06-29
SG149695A1 (en) 2009-02-27
WO2003068743A1 (en) 2003-08-21
CA2472822A1 (en) 2003-08-21
JP4435571B2 (ja) 2010-03-17
JP2005525341A (ja) 2005-08-25
IS7381A (is) 2004-08-03
ATE480518T1 (de) 2010-09-15
EP1478624A1 (en) 2004-11-24
PL372538A1 (en) 2005-07-25
RU2004122114A (ru) 2005-05-27
RU2007146928A (ru) 2009-06-27

Similar Documents

Publication Publication Date Title
CN100352807C (zh) 被取代的哌啶化合物
US7348324B2 (en) Cyclic amine compounds as CCR5 antagonists
EP1140834A1 (en) Heterocyclic piperidines as modulators of chemokine receptor activity
WO2001087839A1 (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
EP1430050B1 (en) Piperidine derivatives and their use as modulators of chemokine (especially ccr3) activity
WO2003042178A1 (en) Novel piperidine derivatives as modulators of chemokine receptors
WO2003042205A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
AU2002353691A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
NZ555770A (en) Heterocyclic piperazine-carboxamide compounds as CCR2B antagonists
US20040122049A1 (en) Novel piperidine derivatives as modulators of chemokine receptor
WO2008100621A2 (en) Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
EP1448524A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
KR20070107024A (ko) 신규 피리딘 화합물
WO2005118579A2 (en) Thiazole derivatives as chemokine receptor antagonists
WO2000078747A1 (en) Acylhydrazine derivatives, process for preparing the same and use thereof
CN100564358C (zh) 一种制备4-(3,4-二氯苯氧基)哌啶的方法
CN101600691A (zh) 作为趋化因子受体活性调节剂的哌啶基衍生物
CN101128427A (zh) 用作ccr2b拮抗剂的杂环化合物
NZ541682A (en) Chemical compounds
JPWO2000078747A1 (ja) アシルヒドラジン誘導体、その製造法及び用途
AU2002349840A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
JP2001278882A (ja) アシルヒドラジン誘導体、その製造法及び用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071205

Termination date: 20110217